Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?

  • Novartis AG NVS is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG RHHBY, triggering speculation about where the Company will spend the money. 
  • Another significant acquisition could be next. Alnylam Pharmaceuticals Inc ALNY is a prime potential buyout target for Novartis, Bloomberg reported, citing people with knowledge of the matter.
  • Alnylam is the developer of the RNA interference (RNAi) technology behind Novartis' newly acquired cholesterol drug Leqvio (inclisiran).
  • The revelation follows Novo Nordisk A/S's NVO announcement that it is shelling out $3.3 billion to purchase clinical-stage RNAi biotech Dicerna Pharmaceuticals Inc DRNA.
  • The report added that Vertex Pharmaceuticals Inc VRTXIntellia Therapeutics Inc NTLA, Biogen Inc BIIBIncyte Corp INCY, and BioMarin Pharmaceutical Inc BMRN are among a range of other companies seen as potential targets.
  • Also Read: Novartis Mulls Strategic Options For Sandoz, Reaffirms FY21 Outlook.
  • Price Action: ALNY shares are up 4.60% at $180.68 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLong IdeasM&ANewsHealth CareRumorsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!